rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
|
23676790 |
2013 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.
|
23355941 |
2012 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
|
20607847 |
2010 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
|
20557306 |
2010 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
|
19768693 |
2010 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
|
19557636 |
2009 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-associated mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematologic or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.
|
17189410 |
2006 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
|
0.710 |
GeneticVariation
|
BEFREE |
We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-associated mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematologic or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.
|
17189410 |
2006 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
|
14745431 |
2004 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia.
|
15381060 |
2004 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.
|
12783380 |
2003 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
|
12623848 |
2003 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
|
12399961 |
2002 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
|
11964322 |
2002 |
rs121913457
|
|
Myeloid Leukemia, Chronic
|
C |
0.710 |
GeneticVariation
|
CLINVAR |
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
|
12130516 |
2002 |